Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether a process has been established to evaluate future prophylactic treatments for covid-19.

The PROTECT-V clinical trial tests several treatments intended to reduce the risk of confirmed symptomatic COVID-19 infections in vulnerable renal and immunosuppressed patients and the associated risk of hospitalisation and death. The study focuses on prophylactic drugs administered over a six-month period to test the effectiveness at reducing the spread of the virus among those who may be exposed at regular hospital check-ups or dialysis appointments.